FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307584521> ?p ?o ?g. }

• W4307584521 endingPage "193" @default.
• W4307584521 startingPage "181" @default.
• W4307584521 abstract "The phase 3 PACIFIC trial established consolidation therapy with durvalumab as standard of care for patients with unresectable, stage III NSCLC and no disease progression after definitive chemoradiotherapy (CRT). The observational PACIFIC-R study assesses the real-world effectiveness of durvalumab in patients from an early access program. Here, we report treatment characteristics and a preplanned analysis of real-world progression-free survival (rwPFS).PACIFIC-R (NCT03798535) is an ongoing, international, retrospective study of patients who started durvalumab (intravenously; 10 mg/kg every 2 wk) within an early access program between September 2017 and December 2018. The primary end points are investigator-assessed rwPFS and overall survival (analyzed by Kaplan-Meier method).As of November 30, 2020, the full analysis set comprised 1399 patients from 11 countries (median follow-up duration, 23.5 mo). Patients received durvalumab for a median of 11.0 months. Median rwPFS was 21.7 months (95% confidence interval: 19.1-24.5). RwPFS was numerically longer among patients who received concurrent versus sequential CRT (median, 23.7 versus 19.3 mo) and among patients with programmed cell death-ligand 1 expression greater than or equal to 1% versus less than 1% (22.4 versus 15.6 mo). Overall, 16.5% of the patients had adverse events leading to treatment discontinuation; 9.5% of all patients discontinued because of pneumonitis or interstitial lung disease.Consolidation durvalumab after definitive CRT was well tolerated and effective in this large, real-world cohort study of patients with unresectable, stage III NSCLC. As expected, rwPFS was longer among patients who received concurrent versus sequential CRT and patients with higher programmed cell death-ligand 1 expression. Nevertheless, favorable rwPFS outcomes were observed regardless of these factors." @default.
• W4307584521 created "2022-11-03" @default.
• W4307584521 creator A5000601939 @default.
• W4307584521 creator A5004732154 @default.
• W4307584521 creator A5016370905 @default.
• W4307584521 creator A5022776597 @default.
• W4307584521 creator A5022986634 @default.
• W4307584521 creator A5024968173 @default.
• W4307584521 creator A5025630398 @default.
• W4307584521 creator A5027231637 @default.
• W4307584521 creator A5028935678 @default.
• W4307584521 creator A5034359692 @default.
• W4307584521 creator A5038253010 @default.
• W4307584521 creator A5045959942 @default.
• W4307584521 creator A5050766137 @default.
• W4307584521 creator A5052155838 @default.
• W4307584521 creator A5054054946 @default.
• W4307584521 creator A5063300526 @default.
• W4307584521 creator A5064710359 @default.
• W4307584521 creator A5065771929 @default.
• W4307584521 creator A5070979123 @default.
• W4307584521 creator A5084689468 @default.
• W4307584521 creator A5088970346 @default.
• W4307584521 creator A5090329560 @default.
• W4307584521 creator A5091509029 @default.
• W4307584521 date "2023-02-01" @default.
• W4307584521 modified "2023-10-16" @default.
• W4307584521 title "Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study" @default.
• W4307584521 cites W1548882558 @default.
• W4307584521 cites W1968899146 @default.
• W4307584521 cites W2052727153 @default.
• W4307584521 cites W2098564635 @default.
• W4307584521 cites W2104701073 @default.
• W4307584521 cites W2110469369 @default.
• W4307584521 cites W2123176392 @default.
• W4307584521 cites W2138705226 @default.
• W4307584521 cites W2140469315 @default.
• W4307584521 cites W2149089484 @default.
• W4307584521 cites W2152939220 @default.
• W4307584521 cites W2153169173 @default.
• W4307584521 cites W2159094759 @default.
• W4307584521 cites W2263280562 @default.
• W4307584521 cites W2275338432 @default.
• W4307584521 cites W2586810147 @default.
• W4307584521 cites W2618173228 @default.
• W4307584521 cites W2753065806 @default.
• W4307584521 cites W2776144880 @default.
• W4307584521 cites W2893824814 @default.
• W4307584521 cites W2954822605 @default.
• W4307584521 cites W2978349873 @default.
• W4307584521 cites W2980537150 @default.
• W4307584521 cites W2990633213 @default.
• W4307584521 cites W2995072671 @default.
• W4307584521 cites W3010768695 @default.
• W4307584521 cites W3014516696 @default.
• W4307584521 cites W3015017936 @default.
• W4307584521 cites W3025106418 @default.
• W4307584521 cites W3028746215 @default.
• W4307584521 cites W3040551754 @default.
• W4307584521 cites W3046914523 @default.
• W4307584521 cites W3094020015 @default.
• W4307584521 cites W3107857442 @default.
• W4307584521 cites W3108819942 @default.
• W4307584521 cites W3134670533 @default.
• W4307584521 cites W3150122335 @default.
• W4307584521 cites W3165420531 @default.
• W4307584521 cites W3166324988 @default.
• W4307584521 cites W3197329693 @default.
• W4307584521 cites W3203773970 @default.
• W4307584521 cites W3210186366 @default.
• W4307584521 cites W4200416818 @default.
• W4307584521 cites W4226175083 @default.
• W4307584521 cites W4290785735 @default.
• W4307584521 doi "https://doi.org/10.1016/j.jtho.2022.10.003" @default.
• W4307584521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36307040" @default.
• W4307584521 hasPublicationYear "2023" @default.
• W4307584521 type Work @default.
• W4307584521 citedByCount "38" @default.
• W4307584521 countsByYear W43075845212022 @default.
• W4307584521 countsByYear W43075845212023 @default.
• W4307584521 crossrefType "journal-article" @default.
• W4307584521 hasAuthorship W4307584521A5000601939 @default.
• W4307584521 hasAuthorship W4307584521A5004732154 @default.
• W4307584521 hasAuthorship W4307584521A5016370905 @default.
• W4307584521 hasAuthorship W4307584521A5022776597 @default.
• W4307584521 hasAuthorship W4307584521A5022986634 @default.
• W4307584521 hasAuthorship W4307584521A5024968173 @default.
• W4307584521 hasAuthorship W4307584521A5025630398 @default.
• W4307584521 hasAuthorship W4307584521A5027231637 @default.
• W4307584521 hasAuthorship W4307584521A5028935678 @default.
• W4307584521 hasAuthorship W4307584521A5034359692 @default.
• W4307584521 hasAuthorship W4307584521A5038253010 @default.
• W4307584521 hasAuthorship W4307584521A5045959942 @default.
• W4307584521 hasAuthorship W4307584521A5050766137 @default.
• W4307584521 hasAuthorship W4307584521A5052155838 @default.
• W4307584521 hasAuthorship W4307584521A5054054946 @default.
• W4307584521 hasAuthorship W4307584521A5063300526 @default.
• W4307584521 hasAuthorship W4307584521A5064710359 @default.

• next